随着跨国药企上半年财报季落幕，全球药品销售TOP50榜单基本揭晓。根据Insight数据库，许多意料之中的变化发生了，比如诺和诺德的司美格鲁肽（Ozempic、Rybelsus、Wegovy），以超166亿美元的销售额超越默沙东的K药（Keytruda）成为新一代药王；礼来的替尔泊肽（Mounjaro、Zepbound）以121.3%的销售增长率，展现出最大的成长潜力；半年销售额超过100亿美元的...
Source Link随着跨国药企上半年财报季落幕，全球药品销售TOP50榜单基本揭晓。根据Insight数据库，许多意料之中的变化发生了，比如诺和诺德的司美格鲁肽（Ozempic、Rybelsus、Wegovy），以超166亿美元的销售额超越默沙东的K药（Keytruda）成为新一代药王；礼来的替尔泊肽（Mounjaro、Zepbound）以121.3%的销售增长率，展现出最大的成长潜力；半年销售额超过100亿美元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.